Effect of epoetin beta pegol treatment on renal anemia and blood pressure control in non-dialytic CKD patients

Effect of epoetin beta pegol treatment on renal anemia and blood pressure control in non-dialytic CKD patients - Effect of epoetin beta pegol on renal anemia and blood pressure in non-dialytic CKD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009449

Enrollment

100

Registered

2013-01-01

Start date

2013-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-dyalitic chronic kidney disease (CKD)

Interventions

Epoetin beta pegol injection to treat renal anemia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Chronic kidney disease stage 4 and 5, non-dialytic 2. Hb level lower than 11g/dl 3. Longer than 6 months of therapeutic period estimated until initiation of dialysis 4. Volantary consent obtained after adequate explanation on the study

Exclusion criteria

Exclusion criteria: 1. Allergic to erythropoiesis stimulating agents (ESA) 2. Either malignant diseases, severe infectious diseases, or significant adverse conditions complicated 3. Other inadequate occasions assessed by the attending physician

Design outcomes

Primary

Measure	Time frame
Blood Hb level before and after epoetin beta pegol treatment and mean blood pressure as well as its fluctuation during outpatient clinic.	—

Secondary

Measure	Time frame
Correlation between blood pressure fluctuation and incidence of cardiovascular events before and after epoetin beta pegol treatment.	—

Countries

Japan

Contacts

Public ContactKenichiro Asano

Kurashiki Central Hospital Nephrology

ka11734@kchnet.or.jp086-422-0210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026